Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             59 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 African self-sufficiency in cancer control Tawfiles, Davidi

26 7 p. e342
artikel
2 Analysis of drug consumption and expenditure of WHO essential medicines for cancer in 40 countries and regions between 2012 and 2022: a multinational drug use study Jiao, Yuanshi

26 7 p. 877-886
artikel
3 2025 ASCO Annual Meeting Gourd, Katherine

26 7 p. 841
artikel
4 Benchmarking infrastructure for cancer control in Commonwealth countries: a population-based observational study Reddy, Che L

26 7 p. 924-935
artikel
5 Bridging borders for resilience in cancer control in the Middle East: a strategic alliance of Saudi Arabia, Qatar, and Jordan Jafar, Hanan

26 7 p. e390-e397
artikel
6 Bridging borders in cancer control Kutluk, Tezer

26 7 p. 835-836
artikel
7 Bridging tumour classification and treatment Subbiah, Vivek

26 7 p. e343-e344
artikel
8 Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial Agarwal, Neeraj

26 7 p. 860-876
artikel
9 Cancer care in Bahrain: progress, challenges, and strategic priorities Hamadeh, Randah R

26 7 p. 830-831
artikel
10 Cancer control in the Middle East Prowse, Jamie

26 7 p. 829-830
artikel
11 Cancer control in the Middle East: Kuwait perspective Al-Naaimi, Meshari

26 7 p. 832-833
artikel
12 Cancer control in the United Arab Emirates Mukherji, Deborah

26 7 p. e381-e389
artikel
13 Cancer took centre stage at the World Health Assembly Adepoju, Paul

26 7 p. 839
artikel
14 Considerations for results of the patient-reported outcome analyses of the TALAPRO-2 trial de Boissieu, Paul

26 7 p. e345
artikel
15 CONTACT-02 and beyond: rethinking immunotherapy strategies in metastatic prostate cancer Mukherji, Deborah

26 7 p. 819-821
artikel
16 Correction to Lancet Oncol 2024; 25: 1614–24
26 7 p. e349
artikel
17 Correction to Lancet Oncol 2025; 26: 503–15
26 7 p. e349
artikel
18 Correction to Lancet Oncol 2025; 26: 571–82
26 7 p. e349
artikel
19 Correction to Lancet Oncol 2025; 26: 924–35
26 7 p. e349
artikel
20 Correction to Lancet Oncol 2025; 26: e46–54
26 7 p. e349
artikel
21 Correction to Lancet Oncol 2025; 26: e320–30
26 7 p. e349
artikel
22 Demystifying the WHO Model Lists of Essential Medicines for cancer care Trapani, Dario

26 7 p. 821-823
artikel
23 England changes cervical cancer screening to every 5 years Kirby, Tony

26 7 p. e350
artikel
24 Equity in cancer genomics in the UK: a cross-sectional analysis of a national cancer cohort Nguyen, T

26 7 p. 971-980
artikel
25 First-in-world “Trojan horse” drug offered to multiple myeloma patients in England Burki, Talha

26 7 p. e351
artikel
26 From conflict to care: rebuilding Syria's oncology infrastructure Tawfiles, Davidi

26 7 p. 833-835
artikel
27 Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial Fizazi, Karim

26 7 p. 948-959
artikel
28 Hormonal therapy for young-onset breast cancer: current understanding and lessons Lévy, Christelle

26 7 p. 824-825
artikel
29 Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group O’Brien, Katie M

26 7 p. 911-923
artikel
30 Improved recruitment equity in a UK cancer genomic testing programme Evans, D Gareth

26 7 p. 827-829
artikel
31 Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial Tree, Alison C

26 7 p. 936-947
artikel
32 Millions could lose Medicaid coverage under US budget bill Devi, Sharmila

26 7 p. 838
artikel
33 Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial Saito, Mitsue

26 7 p. 960-970
artikel
34 Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy Layman, Rachel M

26 7 p. e332-e333
artikel
35 Partial-breast irradiation: has the dust finally settled? Krug, David

26 7 p. 823-824
artikel
36 Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial Kirby, Anna M

26 7 p. 898-910
artikel
37 Politics and pharma: hurdles in UK science ambitions The Lancet Oncology,

26 7 p. 817
artikel
38 Practice standard in British Colombia impacting opioid prescriptions for people with cancer Burki, Talha

26 7 p. 837
artikel
39 Qatar national cancer care and research: pioneering strategies for global health excellence Al-Thani, Mohammed Bin Hamed

26 7 p. e369-e380
artikel
40 RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continues Vis, André N

26 7 p. e334
artikel
41 RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continues Aluwini, Shafak

26 7 p. e335
artikel
42 Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors de Velasco, Guillermo

26 7 p. e346
artikel
43 Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors Larcher, Alessandro

26 7 p. e347
artikel
44 Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply Srinivasan, Ramaprasad

26 7 p. e348
artikel
45 Rwanda provides free treatment to all cancer patients Nakkazi, Esther

26 7 p. 840
artikel
46 SANO trial: innovations, risks, and unanswered questions Kapoor, Akhil

26 7 p. e336
artikel
47 SANO trial: innovations, risks, and unanswered questions Markar, Sheraz R

26 7 p. e338
artikel
48 SANO trial: innovations, risks, and unanswered questions Housman, Brian

26 7 p. e337
artikel
49 SANO trial: innovations, risks, and unanswered questions Oruç, Ahmet

26 7 p. e339
artikel
50 SANO trial: innovations, risks, and unanswered questions – Authors' reply van der Wilk, Berend J

26 7 p. e340-e341
artikel
51 Setting the PACE for prostate radiotherapy Nickols, Nicholas G

26 7 p. 826-827
artikel
52 Solutions for tackling the global surgery crisis in west Africa Cheng, Leo

26 7 p. 843-845
artikel
53 Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial Zhou, Caicun

26 7 p. 887-897
artikel
54 The CANDLE mission begins in EU countries Das, Manjulika

26 7 p. 842
artikel
55 Towards a comprehensive cancer control policy in Saudi Arabia Alessy, Saleh A

26 7 p. e360-e368
artikel
56 Transforming cancer care in Jordan: a 10-year comprehensive patient-centred strategy guided by local experts Abdel-Razeq, Hikmat

26 7 p. e352-e359
artikel
57 You are her son, not her doctor Eyrich, Nicholas W

26 7 p. 846
artikel
58 Zanidatamab, a bispecific monoclonal antibody for HER2-positive gastro-oesophageal adenocarcinoma patients: a new hope? Coutzac, Clélia

26 7 p. 818-819
artikel
59 Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study Elimova, Elena

26 7 p. 847-859
artikel
                             59 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland